Stock Loans Against Israel-Listed Equity
Institutional securities-backed lending against shares listed on Israel’s principal equity exchanges — for controlling shareholders, founders, and family offices holding positions on the ISA-regulated market.
Israel equity markets.
The firm structures stock loans against shares listed on Israel’s one principal cash equity venue. The instrument allows founders, family offices, controlling shareholders, and concentrated single-stock holders to release liquidity against their Israel-listed position — without selling, and without disturbing voting control or the share register. Beneficial ownership remains with the borrower throughout. The full position is recovered on repayment.
Indicative terms are calibrated to the specific position. Loan-to-value is set against the underlying’s single-stock liquidity and free float. Tenor typically runs twelve to thirty-six months for institutional transactions. Recourse profiles span non-recourse, limited-recourse, and full-recourse — chosen against the borrower’s downside-protection objectives. Loans can be denominated in ILS or in cross-currency structures (USD, EUR, GBP, or another major currency) depending on the borrower’s redeployment requirements.
Israel stock loans at a glance:
| Listed venue | Tel Aviv Stock Exchange (TASE) |
|---|---|
| Regulator | Israel Securities Authority (ISA) |
| Currency | ILS, with cross-currency options |
| Principal indices | TA-35, TA-125, TA SME 60 |
| Tenor | 12–36 months (institutional) |
| Recourse profile | Non-recourse, limited-recourse, or full-recourse |
| Loan-to-value | Calibrated per position |
Regulatory references for any specific transaction are mapped at the structuring stage with the borrower’s chosen counsel. The information above is published for general orientation and is not legal advice.
On this market, specifically.
Disclosure and regulation
Israel’s Securities Law requires substantial-holdings notification at 5%, while interested-party rules can engage at lower levels, so a controlling or connected holder can carry disclosure obligations before the ordinary 5% line is reached. That matters for a pledge because the review must weigh not just the raw stake but the holder’s status. A defining feature of the market is the overlap with Israeli technology and biotechnology issuers that are dual-listed in the United States; for such a position the pledge is mapped against both the Israeli regime and the US reporting obligations, and the choice of where the collateral sits shapes custody and settlement.
An illustrative example
A holder of ILS 180 million in a TA-35 constituent, at an illustrative loan-to-value of 45% — within the disclosed 20–65% range — releases roughly ILS 81 million in cash while retaining the shares. For an issuer dual-listed in the United States, the loan can be drawn in ILS or in USD against the US line, to suit the holder’s reporting currency and where the shares are most efficiently held. The numbers are round and illustrative, shown to convey how a pledge is sized rather than to signal a rate, a term, or a particular structure.
Illustrative only — not an offer, a quotation, or a commitment to lend.
Each Israel exchange, covered.
What people most often ask about Israel.
Q · 01 What is the typical loan-to-value for a stock loan against TASE-listed positions?
Q · 02 Which TASE-listed segments are eligible for stock loans?
Q · 03 In which currency can a TASE stock loan be denominated?
Q · 04 Are there foreign-ownership constraints on TASE-listed shares relevant to a pledge?
Countries adjacent to Israel.
A specific Israel position to discuss?
Submit a confidential enquiry. A senior principal will respond within one business day.